Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZBIO vs UPB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ZBIO Captures Overall Composite Edge (49.4 HOLD vs 43.6 HOLD), While UPB Leads 4–1 on Growth & Valuation Pillars
ZBIO Overall Winner
6-Pillar Tally: ZBIO 1 – 4 UPB (1 Tie)
Matrix Metrics: ZBIO 5 – 2 UPB
As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) captures the overall head-to-head institutional edge over Upstream Bio, Inc. (UPB) on higher Unified Composite conviction (49.4/100 HOLD vs. 43.6/100 HOLD) after splitting the core matrix 5–2 (led by Options & Positioning), while UPB wins 4–1 across the 6-pillar growth and valuation breakdown. ZBIO trades at $27.93 (N/M Forward P/E, -2747.5% operating margin) versus UPB at $2.15 (N/M Forward P/E, -6116.0% operating margin).
- Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. UPB 43.6/100 HOLD) and 1.16β · 59% Vol risk profile, whereas UPB leads top-line expansion (-42.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile UPB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ZBIO vs UPB
ZBIO
Head-to-Head Winner
Zenas BioPharma, Inc. Common Stock
$27.93
-0.29% 1D
Market Cap
$1.9B
TTM Revenue
$11M
Forward P/E
N/M
Beta / 30D Vol
1.16β · 59% Vol
Unified Composite Score
49.4
HOLD
Tech 44.0
Fund 53.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
UPB
Upstream Bio, Inc. Common Stock
$2.15
-22.66% 1D
Market Cap
$156.8M
TTM Revenue
$2.9M
Forward P/E
N/M
Beta / 30D Vol
1.70β · 120% Vol
Unified Composite Score
43.6
HOLD
Tech 25.0
Fund 52.0
Flow 66.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ZBIO 1 – 4 UPB)
1. Valuation Multiples
UPB
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
38.4x
2. Growth & Scale
UPB
Revenue Growth (YoY)
-100.0%
-42.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$11M
$2.9M
Market Cap
$1.9B
$156.8M
3. Profitability & Quality
UPB
Gross Margin
N/A
100.0%
Operating Margin
-2747.5%
-6116.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-265.1%
-53.5%
4. Balance Sheet & Cash Flow
UPB
Cash Generation (TTM)
-$273M
-$168M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$177M Net Cash
$47M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ZBIO
Options Structure Phase
CONSOLIDATION
BREAKDOWN
Current IV / %ile
95.3% (12th %ile)
86.7% (17th %ile)
Put/Call OI Skew
N/A
4.72x (Put-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Distribution
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ZBIO (5) vs UPB (2)| Institutional Metric | ZBIO | UPB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.9B | $156.8M | ZBIO | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -100.0% | -42.2% | UPB | |
| Operating Margin (TTM) | -2747.5% | -6116.0% | ZBIO | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -265.1% | -53.5% | UPB | |
| 52-Week Range Position | 46% ($14–$45) | 0% ($2–$34) | ZBIO | |
| Beta / 30D Volatility | 1.16β · 59% Vol | 1.70β · 120% Vol | ZBIO | |
| Unified Institutional Score | 49.4 / 100 (HOLD) | 43.6 / 100 (HOLD) | ZBIO | |
| Trailing 12M Revenue (USD) | $11M | $2.9M | Scale | |
| Gross Profit Margin (TTM) | N/A | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 38.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$273M ($177M Net Cash) | -$168M ($47M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ZBIO +34.54 pp
3M Horizon
ZBIO +56.14 pp
6M Horizon
ZBIO +139.91 pp
1Y Horizon
ZBIO +69.11 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ZBIO Revenue | UPB Revenue | ZBIO Op. Margin | UPB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2023 | $50M | $0M | -74.3% | -1685.5% | ZBIO |
| FY2024 | $10M | $0M | -3277.8% | -3281.2% | ZBIO |
| FY2025 | $10M | $0M | -3830.6% | -5618.8% | ZBIO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ZBIO
CONSOLIDATION
Current IV
95.3%
IV Percentile
12th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
UPB
BREAKDOWN
Current IV
86.7%
IV Percentile
17th %ile
Put/Call OI Skew
4.72x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact UPB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ZBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
UPB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ZBIO vs UPB Key Questions & Quantitative Answers
As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) captures the overall head-to-head institutional edge over Upstream Bio, Inc. (UPB) on higher Unified Composite conviction (49.4/100 HOLD vs. 43.6/100 HOLD) after splitting the core matrix 5–2 (led by Options & Positioning), while UPB wins 4–1 across the 6-pillar growth and valuation breakdown. ZBIO trades at $27.93 (N/M Forward P/E, -2747.5% operating margin) versus UPB at $2.15 (N/M Forward P/E, -6116.0% operating margin). Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. UPB 43.6/100 HOLD) and 1.16β · 59% Vol risk profile, whereas UPB leads top-line expansion (-42.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile UPB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
UPB leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with UPB at -42.2% YoY revenue growth and +0.0% YoY earnings growth on $2.9M TTM revenue (100.0% gross margin, -6116.0% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), ZBIO cumulative revenue shifted -80.0% while UPB shifted N/A. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UPB.
UPB screens cheaper on headline valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas UPB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 38.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus UPB (-53.5% ROE) capital efficiency.
In options market volatility and institutional positioning, ZBIO carries 95.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, UPB carries 86.7% implied volatility (17th %ile, Compressed (<25th %ile)), a 4.72x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 120% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
UPB vs ZBIO · Reverse Pair
ZBIO vs MBX
· Sector Peer
ZBIO vs BCAX
· Sector Peer
ZBIO vs ALMS
· Sector Peer
UPB vs BCAX
· Sector Peer
UPB vs MBX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem